Vertex Pharmaceuticals has discontinued its collaborative cystic fibrosis (CF) program with Moderna, citing concerns related to lung inflammation. The decision marks a significant shift for both companies, which had aimed to develop a new treatment option for CF patients not currently served by existing therapies. The halted program was designed to address the needs of…
Odyssey Therapeutics, led by Gary Glick, has officially entered the public markets, marking a significant milestone for the Boston-based biotechnology company. The move comes after the company postponed its initial public offering (IPO) plans last year. With this IPO, Odyssey Therapeutics becomes the latest in a series of biotech firms in the region to go…
A life science property in Waltham has reached full occupancy, with two biotech companies now leasing the entire space. The building, which spans nearly 144,000 square feet, is fully leased according to recent reports. This development highlights ongoing demand for specialized laboratory and office space in the Greater Boston area, a region recognized for its…
Generate Biomedicines, a Somerville-based company specializing in AI-driven drug development, has completed a $400 million initial public offering (IPO). The offering matches the record for the largest biotech IPO set in 2020, signaling renewed activity in the sector after a period of limited public offerings. The company’s successful entry into the public markets is being…
Boston’s startup ecosystem continued to show strong momentum in February, with local companies raising nearly $1 billion in venture capital during the month. The influx of funding highlights the city’s ongoing appeal to investors in both the technology and biotechnology sectors. According to recent reporting, two new unicorns—privately held startups valued at over $1 billion—emerged…
